Here is why Angiodynamics (NASDAQ:ANGO) can still attract institutional investors


USD 12.20  0.53  4.16%   

In this article, we will outline Angiodynamics. We will evaluate if Angiodynamics shares are reasonably priced going into November. In this post, I will also go over a few different drivers affecting Angiodynamics' products and services, and explain how it may impact Angiodynamics institutional investors.
Published over a month ago
View all stories for AngioDynamics | View All Stories
Our investment recommendation module complements current analysts and expert consensus on Angiodynamics. It analyzes the firm potential to grow using all fundamental, technical, and market related data available at the time.

How important is AngioDynamics's Liquidity

AngioDynamics financial leverage refers to using borrowed capital as a funding source to finance AngioDynamics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. AngioDynamics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between AngioDynamics's total debt and its cash.

How does AngioDynamics utilize its cash?

To perform a cash flow analysis of AngioDynamics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash AngioDynamics is receiving and how much cash it distributes out in a given period. The AngioDynamics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
AngioDynamics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (7.38 Million)

What did AngioDynamics file with SEC?

The SEC filings are financial statements or other formal documents of AngioDynamics that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.
Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to AngioDynamics shareholders may or may not be submitted as SEC does not always require it.
31st of August 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Termination of a Material Definitive Agreement. Entry into a Material Definitive Agreement
9th of February 2022
Unclassified Corporate Event
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to AngioDynamics shareholders may or may not be submitted as SEC does not always require it.

Purchase by Stephen Trowbridge of 1083 shares of Angiodynamics

Legal trades by AngioDynamics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Angiodynamics insider trading alert for perchase of common stock by Stephen Trowbridge, EVP and CFO, on 12th of October 2022. This event was filed by Angiodynamics Inc with SEC on 2022-10-12. Statement of changes in beneficial ownership - SEC Form 4. Stephen Trowbridge currently serves as sr. vp, general counsel and assistant secretary of Angiodynamics [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving AngioDynamics Investor Appetite?

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Angiodynamics has an asset utilization ratio of 43.54 percent. This suggests that the company is making $0.44 for each dollar of assets. An increasing asset utilization means that Angiodynamics is more efficient with each dollar of assets it utilizes for everyday operations.

Angiodynamics has 81 percent chance to finish above $21 in November

The variance is down to 4.03 as of today. Angiodynamics has relatively low volatility with skewness of 0.3 and kurtosis of -0.4. However, we advise all investors to independently investigate Angiodynamics to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Angiodynamics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Angiodynamics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Takeaway on Angiodynamics Investment

Whereas some other companies in the medical instruments & supplies industry are either recovering or due for a correction, Angiodynamics may not be performing as strong as the other in terms of long-term growth potentials. While some institutional investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Angiodynamics.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of AngioDynamics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to